镭-223对骨转移去势抵抗性前列腺癌骨肿瘤微环境的免疫调节空间图谱
该研究对24例接受镭-223治疗的骨转移去势抵抗性前列腺癌(bmCRPC)患者进行基线及治疗终点髂骨骨髓活检,其中3例配对标本含肿瘤者行多重免疫荧光。结果显示基线肿瘤诱导骨周围CD68+巨噬细胞富集,肿瘤细胞呈大片状处T细胞耗竭;镭-223对肿瘤细胞及T细胞亚群的影响异质,肿瘤细胞数与CD3+/CD8+及CD4+/FoxP3+细胞变化呈反向相关。
要点
- 基线时肿瘤诱导骨周围CD68+巨噬细胞富集,肿瘤细胞大片状区域T细胞耗竭。
- 镭-223对肿瘤细胞和T细胞亚群的影响在3例患者中表现异质。
- 肿瘤细胞数变化与CD3+/CD8+及CD4+/FoxP3+细胞变化呈反向相关。
核心结论
- 镭-223治疗前后肿瘤细胞数量变化与CD3+/CD8+及CD4+/FoxP3+细胞变化呈反向相关,但仅基于3例患者。
- 需进一步表征骨肿瘤微环境免疫细胞,以开发增强bmCRPC免疫治疗疗效的策略。
研究设计与样本
- 对24例接受镭-223治疗的bmCRPC患者,在基线和治疗终点行髂骨骨髓活检。
- 对3例配对标本含肿瘤者行多重免疫荧光,检测肿瘤细胞标志物CK、T细胞标志物CD3/CD4/CD8/FOXP3/颗粒酶B、巨噬细胞标志物CD68和CD206。
主要发现
- 3例患者基线时均见CD68+巨噬细胞富集于肿瘤诱导骨周围。
- CD3染色显示肿瘤细胞形成大片状处T细胞耗竭,而肿瘤细胞散在处无此现象。
- 镭-223对肿瘤细胞和T细胞亚群的影响异质:1例肿瘤细胞减少且CD3+/CD8+ T细胞增加;1例骨溶解进展者肿瘤细胞增加且CD3+/CD8+ T细胞减少;1例基线肿瘤细胞高,治疗后适度减少且CD3+/CD8+ T细胞适度增加。
临床怎么用
- 镭-223对骨肿瘤微环境免疫细胞的影响存在个体差异,临床决策需考虑这种异质性。
- 骨肿瘤微环境中的巨噬细胞和T细胞空间分布可能影响免疫治疗策略设计。
局限性
- 免疫荧光分析仅纳入3例含肿瘤的配对标本,样本量小。
- 研究未报告临床结果,仅使用已完成临床试验的样本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) bone lesions are bone-forming, which contribute to an immunosuppressive bone-tumor microenvironment (bone-TME). Targeting PCa-induced bone with the radiopharmaceutical Radium-223 (Ra223) is approved for men with bone-metastatic castration-resistant PCa (bmCRPC). We studied the effect of Ra223 on spatial localization of tumor and immune cells in bmCRPC tumor biopsies to gain insights into therapeutic immunomodulation of the bone-TME. METHODS: Transiliac bone marrow biopsies were performed at baseline and end of treatment (EOT) in 24 patients with bmCRPC treated with Ra223. In three patients with paired specimens containing tumor, multiplex immunofluorescence was performed with antibodies for a tumor cell marker (CK), T-cell markers (CD3, CD4, CD8, FOXP3, and granzyme B), macrophage markers (CD68 [total macrophages] and CD206 [M2-like macrophages]). RESULTS: In all three patients, we observed enrichment of CD68+ macrophages, around tumor-induced bone at baseline. CD3 staining revealed T cell depletion where tumor cells formed large sheets but not where tumor cells were scattered. The effects of Ra223 on tumor cells and T cell subsets were heterogeneous. In one patient, tumor cells were reduced, and CD3+/CD8+ T cells were increased. In a second patient who evidenced osteolytic progression, tumor cells were increased while CD3+/CD8+ T cells were decreased. In a third patient, there was high number of tumor cells at baseline that modestly decreased and the number of CD3+/CD8+ T cells modestly increased after Ra223 treatment. CONCLUSIONS: The changes in tumor cell numbers after Ra223 treatment seemed to be inversely correlated with changes in CD3+/CD8+ and CD4+/FoxP3+ cells, but not with other immune cells, in these 3 patients. Further characterization of immune cells in the bone-TME will be required before developing strategies to enhance immunotherapy efficacy in bmCRPC. CLINICAL TRIAL REGISTRATION: This study does not report the clinical results of a clinical trial, but it does use samples from a completed clinical trial that is registered with clinicaltrials.gov (NCT02135484).
引用
- Corn PG, Yu G, Fan Y, et al. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis. 2025. PMID: 41454189. doi:10.1038/s41391-025-01069-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。